Incyte corp
INCY 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
INCY 近期報酬表現
0.17%
Incyte corp
0.98%
同產業平均
0.02%
S&P500
與 INCY 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
VRTX | Vertex pharmaceuticals inc | 5 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
BMY | Bristol-myers squibb company | 4 分 | 2 分 | 2 分 | 2 分 | 5 分 | |
SNDX | Syndax pharmaceuticals inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
NVS | Novartis ag | 3 分 | 3 分 | 2 分 | 2 分 | 5 分 | |
STTK | Shattuck labs, inc | 3 分 | 4 分 | 3 分 | 3 分 | 1 分 |
- VRTX Vertex pharmaceuticals inc價值 5 分趨勢 3 分波段 2 分籌碼 3 分股利 1 分查看更多
INCY 公司資訊
Incyte Corp. Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.